	Somatostatin receptor
Octreotate
Radionuclide therapy
GEP tumours
Lutetium-177
	follow-up
liver
patients
doses
treatment
therapy
partial remissions
progressive disease
higher
months
Lu-octreotate
somatostatin analogues
tumours
final dose
Lu-octreotate therapy
administration
grade
toxicity grade
stable disease
FSH concentrations
chi-square test
present
high uptake
mCi
complete remission
start
side-effects
uptake

